- Conditions
- Type 1 Diabetes Mellitus, New-onset Type 1 Diabetes Mellitus, T1DM, T1D
- Interventions
- Tocilizumab (TCZ), Placebo, Standard of Care
- Drug · Other
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 6 Years to 17 Years
- Enrollment
- 136 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2020
- U.S. locations
- 17
- States / cities
- San Francisco, California • Stanford, California • New Haven, Connecticut + 14 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 133
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Migraine
- Interventions
- ABP-450, Placebo
- Drug
- Lead sponsor
- AEON Biopharma, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 797 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 54
- States / cities
- Chandler, Arizona • Phoenix, Arizona • Tempe, Arizona + 49 more
- Conditions
- Hepatitis B
- Interventions
- Bepirovirsen, Placebo
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 46 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Austin, Texas
- Conditions
- Solid Tumors
- Interventions
- VX15/2503
- Drug
- Lead sponsor
- Vaccinex Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 2
- States / cities
- Scottsdale, Arizona • San Antonio, Texas
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- RVT-1201, Placebo
- Drug
- Lead sponsor
- Altavant Sciences GmbH
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 20
- States / cities
- Phoenix, Arizona • Sacramento, California • Santa Barbara, California + 17 more
- Conditions
- Lyme Disease
- Interventions
- TP-05 (lotilaner) Low Dose, TP-05 (lotilaner) High Dose, Placebo
- Drug
- Lead sponsor
- Tarsus Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 722 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2027
- U.S. locations
- 19
- States / cities
- Pikesville, Maryland • Brookline, Massachusetts • Fall River, Massachusetts + 16 more
- Conditions
- Onychomycosis
- Interventions
- TDT067, Placebo, Transfersome
- Drug
- Lead sponsor
- Celtic Pharma Development Services
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 738 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 1
- States / cities
- Albequerque, New Mexico
- Conditions
- A/Vietnam/H5N1 Influenza Virus
- Interventions
- 7.5 mcg H5N1 (stored as monobulk), 15 mcg H5N1 (stored as monobulk), 90 mcg H5N1 (stored as monobulk), 90 mcg H5N1 (stored in vials), MF59, MF59 (stored as monobulk)
- Biological · Other
- Lead sponsor
- Biomedical Advanced Research and Development Authority
- Federal
- Eligibility
- 18 Years to 49 Years
- Enrollment
- 422 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2017
- U.S. locations
- 6
- States / cities
- Atlanta, Georgia • Council Bluffs, Iowa • Lenexa, Kansas + 3 more
- Conditions
- Hepatic Impairment
- Interventions
- oral dose of 200 mg pacritinib twice daily (BID)
- Drug
- Lead sponsor
- CTI BioPharma
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 29 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2024
- U.S. locations
- 2
- States / cities
- Orlando, Florida • San Antonio, Texas
- Conditions
- Kidney Transplantation, Renal Transplantation, Renal Transplant Recipient
- Interventions
- Donor-derived Mesenchymal Stromal Cells, alemtuzumab, belatacept, sirolimus, mycophenolate mofetil, mycophenolate acid, prednisone
- Biological · Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 19 Years and older
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2025
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Acute Myocardial Infarction
- Interventions
- AMI MultiStem®
- Biological
- Lead sponsor
- Healios K.K.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 7
- States / cities
- Birmingham, Alabama • Indianapolis, Indiana • Detroit, Michigan + 3 more
- Conditions
- Schizophrenia
- Interventions
- PF-00184562, Olanzapine
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2005
- U.S. locations
- 1
- States / cities
- Austin, Texas
- Conditions
- Post Traumatic Stress Disorder
- Interventions
- Intervention C Daridorexant, Intervention C Placebo
- Drug
- Lead sponsor
- Global Coalition for Adaptive Research
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 200 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2029
- U.S. locations
- 9
- States / cities
- Miami, Florida • Atlanta, Georgia • Tripler AMC, Hawaii + 6 more
- Conditions
- Drug Interactions
- Interventions
- CYP450 Cocktail and Transporter Substrates with Pacritinib, Part 2 -Group A Bosentan 125 mg (CYP450 3A4 inducer) with Pacritinib, Part 2 Group B - Fluconazole (CYP450 3A4 inhibitor) with Pacritinib
- Drug
- Lead sponsor
- CTI BioPharma
- Industry
- Eligibility
- 18 Years to 55 Years · Male only
- Enrollment
- 60 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023
- U.S. locations
- 1
- States / cities
- Austin, Texas
- Conditions
- HIV Infections
- Interventions
- Indinavir sulfate, Ritonavir, Stavudine, Didanosine
- Drug
- Lead sponsor
- PPD Development, LP
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2000
- U.S. locations
- 13
- States / cities
- Berkeley, California • Los Angeles, California • Fort Lauderdale, Florida + 8 more
- Conditions
- Heart Transplant
- Interventions
- tocilizumab, Placebo, Standard of Care Triple IS
- Biological · Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 385 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2025
- U.S. locations
- 20
- States / cities
- Beverly Hills, California • La Jolla, California • Stanford, California + 15 more
- Conditions
- Autoimmune Disorders
- Interventions
- Daratumumab
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 8
- States / cities
- Baltimore, Maryland • Ann Arbor, Michigan • Rochester, Minnesota + 3 more
- Conditions
- Post Traumatic Stress Disorder
- Interventions
- Intervention A Fluoxetine Hydrochloride (HCl), Intervention A Placebo, Intervention B Vilazodone Hydrochloride (HCl), Intervention B Placebo, Intervention C Daridorexant, Intervention C Placebo, Intervention D SLS-002, Intervention D Placebo
- Drug
- Lead sponsor
- Global Coalition for Adaptive Research
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 800 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2029
- U.S. locations
- 9
- States / cities
- Miami, Florida • Atlanta, Georgia • Tripler AMC, Hawaii + 6 more
- Conditions
- Kidney Transplantation, Renal Transplant Recipients
- Interventions
- Lulizumab, Tacrolimus, Thymoglobulin®, Methylprednisolone, Mycophenolate Mofetil, Prednisone
- Biological · Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 70 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Acute Pain, Soft Tissue Injury
- Interventions
- Diclofenac Sodium, Matching Placebo Patch
- Drug
- Lead sponsor
- Cerimon Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 407 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009
- U.S. locations
- 1
- States / cities
- Austin, Texas
- Conditions
- Multiple Sclerosis, Clinically Isolated Syndrome
- Interventions
- Ocrelizumab
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years to 40 Years · Female only
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 4
- States / cities
- San Francisco, California • Aurora, Colorado • Chicago, Illinois + 1 more
- Conditions
- Kidney Failure, Chronic, Catheter-Related Infections
- Interventions
- Neutrolin, Heparin
- Drug
- Lead sponsor
- CorMedix Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 806 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 5
- States / cities
- Riverside, California • San Dimas, California • Miami Gardens, Florida + 2 more
- Conditions
- Healthy
- Interventions
- ALXN1840, Placebo, Moxifloxacin
- Drug
- Lead sponsor
- Alexion Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 57 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- Austin, Texas
- Conditions
- Esophageal Carcinoma, Gastroesophageal Junction Carcinoma
- Interventions
- Not listed
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 11
- States / cities
- Birmingham, Alabama • San Luis Obispo, California • Santa Maria, California + 8 more